Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

Circular RNA: The tiny genetic loops offering new clues to cancer

Circular RNAs in tumorigenesis: an insight into recent research in biogenesis and targeted tumor therapy.

PubMed2 min readAI-assisted summary
Editorial illustration for Circular RNAs in tumorigenesis: an insight into recent research in biogenesis and targeted tumor therapy.
Editorial illustration

Summary

Inside our cells, genetic instructions are typically carried by linear strands of a molecule called messenger RNA, or mRNA. But scientists are paying closer attention to a different shape entirely: circular RNAs. Unlike their straight-line cousins, these molecules form a continuous, unbroken loop. Because they have no exposed ends, they are highly stable. They are also highly specific, meaning different types of tissues and cells produce their own unique sets of these loops. Even though they are abundant in the body, they are usually found in lower amounts than traditional linear RNA.

Researchers have discovered that these genetic loops behave very differently when cancer is present. In tumor cells, the normal patterns of circular RNA are frequently disrupted. Mounting evidence shows that these molecules actually play major roles in how tumors start, how they grow, and how they interact with the body's immune system.

Interestingly, some of the circular RNAs tied to cancer do not just stay inside the tumor. They can travel through the bloodstream and survive for long periods in blood serum. Because they are so stable and specific to certain cells, scientists believe these floating loops could eventually be used as biomarkers, which are measurable biological signs used to detect disease. By testing a patient's blood, doctors might one day be able to diagnose cancer or predict how a tumor will behave.

Why it matters.

The discovery of circular RNAs surviving in the bloodstream opens an exciting door for the future of medicine, particularly for less invasive cancer testing. If doctors can reliably detect these specific loops in a standard blood draw, it could eventually lead to faster, easier, and earlier cancer diagnoses compared to traditional tissue biopsies. Tracking these stable molecules could also help oncologists monitor how a tumor is progressing or responding to treatment over time.

However, it is important to keep in mind that this field of research is still in its early stages. Current literature provides a broad, theoretical look at how these molecules work in a laboratory or pre-clinical setting. The reviewed research lacks specific clinical trial data, exact numbers on patient sample sizes, and quantitative metrics proving exactly how effective these tools will be in the real world. Much more testing is needed before circular RNA tracking becomes a routine part of human cancer care.

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Circular RNA: The tiny genetic loops offering new clues to cancer — Daily Strand